Background:Helicobacter pylori is one of the most common chronic infections and is a leading cause of gastric cancer. There are currently several short-course treatment options available for the treatment of H. pylori. However, there has been a significant increase in global resistance patterns for H. pylori and there is a need for alternative treatment regimens. Nitazoxanide (NTZ) is an anti-protozoal agent that has been evaluated within several studies for the treatment of H. pylori. The objective of this review is to evaluate the efficacy and safety of NTZ-based treatments for a H. pylori infection.Methods: Pubmed (1946-August 2019) and Embase (1947-August 2019) were queried using the following search terms: Helicobacter, Helicobacter infection, Helicobacter pylori, nitazoxanide, tizoxanide, thiazoles, thiazole derivative and NTZ. Appropriate studies were evaluated with varying treatment regimens and cure rates.Results: Ten studies that utilized a NTZ-based treatment for H. pylori were identified from the literature search. Eight of the ten studies demonstrated a cure rate of greater than 80% in at least one NTZ-based treatment arm. Gastrointestinal side effects were the most commonly reported adverse drug reaction in the studies.Conclusions: Nitazoxanide-based treatments appear to be an effective treatment for H. pylori. While the ideal NTZ combination therapy is uncertain, a combination with a proton-pump inhibitor and one to two antibiotics has demonstrated the highest rates of H. pylori eradication. Nitazoxanide-based treatments are well-tolerated and minimal discontinuation due to side effects were reported in the studies.
Keywords: H. pylori; metronidazole resistance; salvage therapy; thiazole; tizoxanide.